0001104659-20-005717.txt : 20200122 0001104659-20-005717.hdr.sgml : 20200122 20200122074949 ACCESSION NUMBER: 0001104659-20-005717 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200122 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200122 DATE AS OF CHANGE: 20200122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 20537561 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 tm205456d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

January 22, 2020

Date of Report (Date of earliest event reported)

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

Illinois		1-2189		36-0698440
(State or other Jurisdiction		(Commission File Number)		(IRS Employer
of Incorporation)				Identification No.)

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (224) 667-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Shares, Without Par Value		ABT		New York Stock Exchange Chicago Stock Exchange, Inc.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02

Results of Operations and Financial Condition

On January 22, 2020, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2019.

Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings from continuing operations excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions and restructuring actions, charges related to cost reduction initiatives, the acquisition of R&D assets, costs associated with the early extinguishment of debt, charges related to impairment of certain assets, and tax benefits associated with specified items, a reduction in the transition tax associated with the Tax Cuts and Jobs Act and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

Item 9.01

Financial Statements and Exhibits

	Exhibit No.		Exhibit

	99.1		Press Release dated January 22, 2020 (furnished pursuant to Item 2.02).

	104		Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ABBOTT LABORATORIES

Date: January 22, 2020	By:	/s/ Brian B. Yoor
		Brian B. Yoor
		Executive Vice President, Finance and Chief Financial Officer

EX-99.1 2 tm205456d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

News Release

Abbott Reports Fourth-Quarter 2019 Results; Announces Strong Forecast for 2020

	·	Fourth-quarter sales growth of 7.1 percent; organic sales growth of 8.5 percent
	·	Fourth-quarter GAAP EPS growth from continuing operations of 59.5 percent and adjusted EPS growth from continuing operations of 17.3 percent
	·	Several businesses achieved double-digit sales growth
	·	Forecast reflects continued top-tier sales and earnings growth for 2020

ABBOTT PARK, Ill., Jan. 22, 2020 — Abbott today announced financial results for the fourth quarter and full year ended Dec. 31, 2019.

	·	Fourth-quarter worldwide sales of $8.3 billion increased 7.1 percent on a reported basis and 8.5 percent on an organic* basis.
	·	Reported diluted EPS from continuing operations under GAAP was $0.59 in the fourth quarter. Adjusted diluted EPS from continuing operations, which excludes specified items, was $0.95, an increase of 17.3 percent versus prior year¹.
	·	Abbott issues full-year 2020 guidance for organic sales growth of 7.0 to 8.0 percent², which excludes the impact of foreign exchange, and diluted EPS from continuing operations on a GAAP basis of $2.35 to $2.45. Projected full-year adjusted diluted EPS from continuing operations is $3.55 to $3.65, reflecting double-digit growth at the mid-point.
	·	Medical Devices sales increased 9.7 percent on a reported basis and 11.3 percent on an organic basis in the fourth quarter. Sales performance was led by double-digit organic sales growth in Heart Failure, Electrophysiology, Structural Heart and Diabetes Care.
	·	Established Pharmaceuticals sales increased 7.8 percent on a reported basis and 10.0 percent on an organic basis in the fourth quarter. Sales performance was led by growth across several countries in Latin America and Asia.
	·	Core Laboratory Diagnostics sales increased 8.4 percent on a reported basis and 10.0 percent on an organic basis in the fourth quarter. Sales performance was led by above-market growth in the U.S. and internationally, where Abbott is achieving continued strong adoption of its Alinity^® family of innovative and highly differentiated diagnostic instruments.

“Our focus on organic growth is driving top-tier performance,” said Miles D. White, chairman and chief executive officer, Abbott. “We're entering 2020 with very good momentum and targeting continued strong growth.”

—more—

* See note on organic growth on the next page.

fourth-Quarter Business Overview

Note: Management believes that measuring sales growth rates on an organic basis is an appropriate way for investors to best understand the underlying performance of the business.

Organic sales growth:

	·	Excludes the results for a non-core business within U.S. Adult Nutrition during the first nine months of 2018 as this business was discontinued during the third quarter 2018; and
	·	Excludes the impact of foreign exchange.

Following are sales by business segment and commentary for the fourth quarter and full year 2019:

Total Company

($ in millions)

											% Change vs. 4Q18
		Sales 4Q19									Reported									Organic
		U.S.			Int'l			Total			U.S.			Int'l			Total			U.S.			Int'l			Total
Total *		2,960			5,354			8,314			7.5			6.9			7.1			7.5			9.1			8.5
Nutrition		789			1,079			1,868			3.6			6.4			5.2			3.6			7.5			5.8
Diagnostics		766			1,292			2,058			9.6			2.4			5.0			9.6			4.6			6.4
Established Pharmaceuticals		—			1,174			1,174			n/a			7.8			7.8			n/a			10.0			10.0
Medical Devices		1,404			1,800			3,204			9.2			10.1			9.7			9.2			12.9			11.3

* Total Q4 2019 Abbott sales from continuing operations include Other Sales of $10 million.

											% Change vs. 12M18
		Sales 12M19									Reported									Organic
		U.S.			Int'l			Total			U.S.			Int'l			Total			U.S.			Int'l			Total
Total *		11,398			20,506			31,904			5.2			3.9			4.3			5.5			8.8			7.7
Nutrition		3,110			4,299			7,409			1.1			3.5			2.5			2.4			7.5			5.3
Diagnostics		2,887			4,826			7,713			6.3			1.0			2.9			6.3			5.7			5.9
Established Pharmaceuticals		—			4,486			4,486			n/a			1.4			1.4			n/a			7.3			7.3
Medical Devices		5,374			6,865			12,239			7.2			8.0			7.6			7.2			13.0			10.5

* Total 12M 2019 Abbott sales from continuing operations include Other Sales of $57 million.

n/a = Not Applicable.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Fourth-quarter 2019 worldwide sales of $8.3 billion increased 7.1 percent on a reported basis. On an organic basis, worldwide sales increased 8.5 percent. Refer to page 17 for a reconciliation of adjusted historical revenue.

2

Nutrition

($ in millions)

											% Change vs. 4Q18
		Sales 4Q19									Reported									Organic
		U.S.			Int'l			Total			U.S.			Int'l			Total			U.S.			Int'l			Total
Total		789			1,079			1,868			3.6			6.4			5.2			3.6			7.5			5.8
Pediatric		473			564			1,037			1.2			3.4			2.4			1.2			4.1			2.8
Adult		316			515			831			7.3			9.9			8.9			7.3			11.5			9.9

											% Change vs. 12M18
		Sales 12M19									Reported									Organic
		U.S.			Int'l			Total			U.S.			Int'l			Total			U.S.			Int'l			Total
Total		3,110			4,299			7,409			1.1			3.5			2.5			2.4			7.5			5.3
Pediatric		1,879			2,282			4,161			1.9			1.3			1.6			1.9			4.6			3.4
Adult		1,231			2,017			3,248			(0.1	)		6.2			3.7			3.2			10.9			7.9

Worldwide Nutrition sales increased 5.2 percent on a reported basis in the fourth quarter. On an organic basis, sales increased 5.8 percent. Refer to page 17 for a reconciliation of adjusted historical revenue.

Worldwide Pediatric Nutrition sales increased 2.4 percent on a reported basis in the fourth quarter, including an unfavorable 0.4 percent effect of foreign exchange, and increased 2.8 percent on an organic basis. International sales increased 3.4 percent on a reported basis and 4.1 percent on an organic basis. Sales growth was led by Abbott's market-leading toddler brands, PediaSure^®and Pedialyte^®.

Worldwide Adult Nutrition sales increased 8.9 percent on a reported basis in the fourth quarter and increased 9.9 percent on an organic basis. International Adult Nutrition sales increased 9.9 percent on a reported basis and 11.5 percent on an organic basis in the fourth quarter. Sales performance in the quarter was led by strong growth of Ensure^®, Abbott's market-leading complete and balanced nutrition brand, and Glucerna^®, Abbott's market-leading diabetes-specific nutrition brand.

3

Diagnostics

($ in millions)

														% Change vs. 4Q18
		Sales 4Q19												Reported												Organic
		U.S.				Int’l				Total				U.S.				Int’l				Total				U.S.				Int’l				Total
Total			766				1,292				2,058				9.6				2.4				5.0				9.6				4.6				6.4
Core Laboratory			293				956				1,249				13.2				7.0				8.4				13.2				9.1				10.0
Molecular			36				80				116				(4.1	)			(6.5	)			(5.7	)			(4.1	)			(4.5	)			(4.4	)
Point of Care			104				33				137				(4.9	)			16.0				(0.5	)			(4.9	)			17.4				(0.2	)
Rapid Diagnostics			333				223				556				13.6				(12.3	)			1.5				13.6				(9.8	)			2.7

														% Change vs. 12M18
		Sales 12M19												Reported												Organic
		U.S.				Int’l				Total				U.S.				Int’l				Total				U.S.				Int’l				Total
Total			2,887				4,826				7,713				6.3				1.0				2.9				6.3				5.7				5.9
Core Laboratory			1,086				3,570				4,656				10.3				4.9				6.2				10.3				9.9				10.0
Molecular			149				293				442				(1.8	)			(11.7	)			(8.6	)			(1.8	)			(8.4	)			(6.3	)
Point of Care			438				123				561				1.4				1.7				1.5				1.4				3.9				1.9
Rapid Diagnostics			1,214				840				2,054				5.7				(9.0	)			(0.8	)			5.7				(4.4	)			1.2

Worldwide Diagnostics sales increased 5.0 percent on a reported basis in the fourth quarter, including an unfavorable 1.4 percent effect of foreign exchange, and increased 6.4 percent on an organic basis.

Core Laboratory Diagnostics sales increased 8.4 percent on a reported basis and 10.0 percent on an organic basis in the fourth quarter. Sales performance was led by above-market growth in the U.S. and internationally, where Abbott is achieving continued strong adoption of its Alinity family of innovative and highly differentiated diagnostic instruments. During the quarter, Abbott announced the Australian Red Cross Blood Services selected its Alinity-S system for the country’s blood and plasma screening.

Molecular Diagnostics sales decreased 5.7 percent on a reported basis in the fourth quarter, including an unfavorable 1.3 percent effect of foreign exchange, and decreased 4.4 percent on an organic basis.

Point of Care Diagnostics sales decreased 0.5 percent on a reported basis in the fourth quarter, including an unfavorable 0.3 percent effect of foreign exchange, and decreased 0.2 percent on an organic basis.

Rapid Diagnostics sales increased 1.5 percent on a reported basis in the fourth quarter, including an unfavorable 1.2 percent effect of foreign exchange, and increased 2.7 percent on an organic basis. Organic sales growth was led by infectious disease testing in developed markets and cardio-metabolic testing globally, partially offset by lower infectious disease testing sales in Africa.

4

Established Pharmaceuticals

($ in millions)

														% Change vs. 4Q18
		Sales 4Q19												Reported												Organic
		U.S.				Int’l				Total				U.S.				Int’l				Total				U.S.				Int’l				Total
Total			—				1,174				1,174				n/a				7.8				7.8				n/a				10.0				10.0
Key Emerging Markets			—				896				896				n/a				7.0				7.0				n/a				9.5				9.5
Other			—				278				278				n/a				10.4				10.4				n/a				11.6				11.6

														% Change vs. 12M18
		Sales 12M19												Reported												Organic
		U.S.				Int’l				Total				U.S.				Int’l				Total				U.S.				Int’l				Total
Total			—				4,486				4,486				n/a				1.4				1.4				n/a				7.3				7.3
Key Emerging Markets			—				3,392				3,392				n/a				0.9				0.9				n/a				7.9				7.9
Other			—				1,094				1,094				n/a				3.3				3.3				n/a				5.6				5.6

Established Pharmaceuticals sales increased 7.8 percent on a reported basis in the fourth quarter, including an unfavorable 2.2 percent effect of foreign exchange, and increased 10.0 percent on an organic basis.

Key Emerging Markets include India, Brazil, Russia and China along with several additional emerging countries that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these geographies increased 7.0 percent on a reported basis in the fourth quarter and increased 9.5 percent on an organic basis, which excludes an unfavorable 2.5 percent effect of foreign exchange. Organic sales growth was led by performance across several geographies in Latin America and Asia.

Other sales increased 10.4 percent on a reported basis in the fourth quarter, including an unfavorable 1.2 percent effect of foreign exchange, and increased 11.6 percent on an organic basis.

5

Medical Devices

($ in millions)

														% Change vs. 4Q18
		Sales 4Q19												Reported												Organic
		U.S.				Int’l				Total				U.S.				Int’l				Total				U.S.				Int’l				Total
Total			1,404				1,800				3,204				9.2				10.1				9.7				9.2				12.9				11.3
Rhythm Management			267				277				544				1.8				2.8				2.3				1.8				5.5				3.7
Electrophysiology			193				266				459				7.7				11.8				10.0				7.7				13.1				10.8
Heart Failure			146				52				198				16.8				(0.8	)			11.6				16.8				2.1				12.5
Vascular			260				454				714				(4.6	)			1.5				(0.8	)			(4.6	)			3.2				0.3
Structural Heart			170				206				376				25.7				7.7				15.1				25.7				10.8				17.0
Neuromodulation			175				47				222				(0.9	)			14.6				2.0				(0.9	)			20.0				3.0
Diabetes Care			193				498				691				43.5				26.0				30.5				43.5				30.3				33.7

Vascular Product Lines:
Coronary and Endovascular^a)			239				452				691				(2.9	)			1.2				(0.3	)			(2.9	)			2.9				0.8

^a)

Includes drug-eluting stents, balloon catheters, guidewires, vascular imaging/diagnostics products, vessel closure, carotid and other coronary and peripheral products.

														% Change vs. 12M18
		Sales 12M19												Reported												Organic
		U.S.				Int’l				Total				U.S.				Int’l				Total				U.S.				Int’l				Total
Total			5,374				6,865				12,239				7.2				8.0				7.6				7.2				13.0				10.5
Rhythm Management			1,057				1,087				2,144				(4.4	)			(0.6	)			(2.5	)			(4.4	)			4.4				0.0
Electrophysiology			742				979				1,721				9.5				10.8				10.2				9.5				14.8				12.5
Heart Failure			574				195				769				22.9				9.4				19.1				22.9				14.1				20.5
Vascular			1,047				1,803				2,850				(7.0	)			0.0				(2.7	)			(7.0	)			4.1				(0.2	)
Structural Heart			616				784				1,400				26.1				4.3				12.9				26.1				9.7				16.2
Neuromodulation			660				171				831				(4.2	)			(1.8	)			(3.8	)			(4.2	)			4.7				(2.4	)
Diabetes Care			678				1,846				2,524				48.3				25.1				30.6				48.3				31.8				35.7

Vascular Product Lines:
Coronary and Endovascular^a)			947				1,793				2,740				(3.9	)			0.0				(1.4	)			(3.9	)			4.1				1.3

^a)

Includes drug-eluting stents, balloon catheters, guidewires, vascular imaging/diagnostics products, vessel closure, carotid and other coronary and peripheral products.

Note: Insertable Cardiac Monitor (ICM) sales, which had previously been reported in Electrophysiology, are now included in Rhythm Management. Historical periods have been adjusted to reflect this change.

Worldwide Medical Devices sales increased 9.7 percent on a reported basis in the fourth quarter and increased 11.3 percent on an organic basis, led by double-digit growth in Electrophysiology, Heart Failure, Structural Heart and Diabetes Care.

In Electrophysiology, growth was led by strong performance in cardiac diagnostic and ablation catheters, which are used to help physicians accurately and effectively treat atrial fibrillation, a form of irregular heartbeat.

6

In Heart Failure, double-digit growth was driven by market adoption of Abbott's HeartMate 3^® left ventricular assist device, which has been shown to improve survival and clinical outcomes in patients with advanced heart failure.

Growth in Structural Heart was led by MitraClip^®, Abbott’s market-leading device for the minimally invasive treatment of mitral regurgitation, or a leaky mitral heart valve. Worldwide sales of MitraClip were $191 million in the fourth quarter, an increase of 27.1 percent on a reported basis and 28.8 percent on an organic basis versus the prior year.

In Diabetes Care, sales increased 30.5 percent on a reported basis and 33.7 percent on an organic basis in the fourth quarter. Sales growth in the quarter was led by FreeStyle Libre^®, Abbott’s revolutionary continuous glucose monitoring system, with worldwide sales of $534 million, an increase of 58.5 percent on a reported basis and 62.4 percent on an organic basis versus the prior year.

7

Abbott issues guidance for 2020

Abbott is issuing full-year 2020 guidance for organic sales growth of 7.0 to 8.0 percent², which excludes the impact of foreign exchange, and diluted earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) of $2.35 to $2.45. Abbott forecasts net specified items for the full year 2020 of $1.20 per share. Specified items include intangible amortization expense, acquisition-related expenses, charges associated with cost reduction initiatives and other expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $3.55 to $3.65 for the full year 2020.

Abbott is issuing first-quarter 2020 guidance for diluted earnings per share from continuing operations under GAAP of $0.40 to $0.42. Abbott forecasts specified items for the first quarter 2020 of $0.29 per share primarily related to intangible amortization, acquisition-related expenses, cost reduction initiatives and other expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $0.69 to $0.71 for the first quarter.

Abbott announces increase in QUARTERLY DIVIDEND

On Dec. 13, 2019, the board of directors of Abbott increased the company's quarterly dividend to $0.36 per share from $0.32 per share, an increase of 12.5 percent. Abbott's cash dividend is payable Feb. 14, 2020, to shareholders of record at the close of business on Jan. 15, 2020.

Abbott has increased its dividend payout for 48 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

8

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.

Abbott will webcast its live fourth-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8:30 a.m. Central time today. An archived edition of the webcast will be available later that day.

— Private Securities Litigation Reform Act of 1995 —

A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors’’ to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Abbott Financial:

Scott Leinenweber, 224-668-0791

Michael Comilla, 224-668-1872

Laura Dauer, 224-667-2299

Abbott Media:

Darcy Ross, 224-667-3655

Elissa Maurer, 224-668-3309

¹ Fourth-quarter 2019 diluted EPS from continuing operations on a GAAP basis reflects 59.5 percent growth.

² Abbott has not provided the GAAP financial measure for organic sales growth on a forward-looking basis because the company is unable to predict the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth.

9

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Fourth Quarter Ended December 31, 2019 and 2018

(in millions, except per share data)

(unaudited)

			4Q19				4Q18				% Change
Net Sales		$	8,314			$	7,765				7.1

Cost of products sold, excluding amortization expense			3,434				3,191				7.7
Amortization of intangible assets			483				488				(1.1	)
Research and development			595				562				6.0
Selling, general, and administrative			2,413				2,359				2.3
Total Operating Cost and Expenses			6,925				6,600				4.9

Operating Earnings			1,389				1,165				19.2

Interest expense, net			139				152				(8.5	)
Net foreign exchange (gain) loss			(2	)			26				n/m
Debt extinguishment costs			63				86				(27.1	)
Other (income) expense, net			(51	)			(46	)			13.5
Earnings from Continuing Operations before taxes			1,240				947				31.1

Tax expense on Earnings from Continuing Operations			191				292				(34.5	)			1	)
Earnings from Continuing Operations			1,049				655				60.3

Earnings from Discontinued Operations, net of taxes			—				(1	)			n/m

Net Earnings		$	1,049			$	654				60.6

Earnings from Continuing Operations, excluding Specified Items, as described below		$	1,705			$	1,444				18.1				2	)

Diluted Earnings per Common Share from:
Continuing Operations		$	0.59			$	0.37				59.5
Discontinued Operations			—				—				n/m
Total		$	0.59			$	0.37				59.5

Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, as described below		$	0.95			$	0.81				17.3				2	)

Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options			1,781				1,774

NOTES:

See tables on page 14 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

10

1)

2018 Tax expense on Earnings from Continuing Operations includes an additional $85 million of tax expense for the transition tax associated with the Tax Cuts and Jobs Act (TCJA).

2)

2019 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $656 million, or $0.36 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions.

2018 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $789 million, or $0.44 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions, as well as additional transition tax related to the TCJA.

11

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Year Ended December 31, 2019 and 2018

(in millions, except per share data)

(unaudited)

			12M19				12M18				% Change
Net Sales		$	31,904			$	30,578				4.3

Cost of products sold, excluding amortization expense			13,231				12,706				4.1
Amortization of intangible assets			1,936				2,178				(11.1	)
Research and development			2,440				2,300				6.1				1	)
Selling, general, and administrative			9,765				9,744				0.2
Total Operating Cost and Expenses			27,372				26,928				1.7

Operating Earnings			4,532				3,650				24.2

Interest expense, net			576				721				(20.1	)
Net foreign exchange (gain) loss			7				28				(74.1	)
Debt extinguishment costs			63				167				(62.6	)
Other (income) expense, net			(191	)			(139	)			38.2
Earnings from Continuing Operations before taxes			4,077				2,873				42.0

Tax expense on Earnings from Continuing Operations			390				539				(27.6	)			2	)
Earnings from Continuing Operations			3,687				2,334				58.0

Earnings from Discontinued Operations, net of taxes			—				34				n/m

Net Earnings		$	3,687			$	2,368				55.7

Earnings from Continuing Operations, excluding Specified Items, as described below		$	5,810			$	5,131				13.2				3	)

Diluted Earnings per Common Share from:
Continuing Operations		$	2.06			$	1.31				57.3
Discontinued Operations			—				0.02				n/m
Total		$	2.06			$	1.33				54.9

Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, as described below		$	3.24			$	2.88				12.5				3	)

Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options			1,781				1,770

NOTES:

See tables on page 15 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

12

1)

In 2019, in conjunction with the acquisition of Cephea Valve Technologies, Inc., Abbott acquired an R&D asset valued at $102 million, which was immediately expensed.

2)

2019 Tax expense on Earnings from Continuing Operations includes the impact of a $86 million reduction of the transition tax associated with the Tax Cuts and Jobs Act (TCJA) and approximately $100 million in excess tax benefits associated with share-based compensation.

2018 Tax expense on Earnings from Continuing Operations includes an additional $120 million of tax expense for the transition tax associated with the TCJA, as well as the impact of approximately $90 million in excess tax benefits associated with share-based compensation.

3)

2019 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $2.123 billion, or $1.18 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions.

2018 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $2.797 billion, or $1.57 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions.

13

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

Fourth Quarter Ended December 31, 2019 and 2018

(in millions, except per share data)

(unaudited)

	4Q19
		As Reported (GAAP)				Specified Items				As Adjusted				% to Sales
Intangible Amortization	$	483			$	(483	)			—
Gross Margin		4,397				545				4,942				59.4	%
R&D		595				(39	)			556				6.7	%
SG&A		2,413				(62	)			2,351				28.3	%
Debt extinguishment costs		63				(63	)			—
Other (income) expense, net		(51	)			(5	)			(56	)
Earnings from Continuing Operations before taxes		1,240				714				1,954
Tax expense on Earnings from Continuing Operations		191				58				249
Earnings from Continuing Operations		1,049				656				1,705
Diluted Earnings per Share from Continuing Operations	$	0.59			$	0.36			$	0.95

Specified items reflect intangible amortization expense of $483 million and other expenses of $231 million, primarily associated with acquisitions, restructuring actions and other expenses. See page 18 for additional details regarding specified items.

	4Q18
		As Reported (GAAP)				Specified Items				As Adjusted				% to Sales
Intangible Amortization	$	488			$	(488	)			—
Gross Margin		4,086				520				4,606				59.3	%
R&D		562				(2	)			560				7.2	%
SG&A		2,359				(91	)			2,268				29.2	%
Net foreign exchange (gain) loss		26				(28	)			(2	)
Debt extinguishment costs		86				(86	)			—
Other (income) expense, net		(46	)			13				(33	)
Earnings from Continuing Operations before taxes		947				714				1,661
Tax expense on Earnings from Continuing Operations		292				(75	)			217
Earnings from Continuing Operations		655				789				1,444
Diluted Earnings per Share from Continuing Operations	$	0.37			$	0.44			$	0.81

Specified items reflect intangible amortization expense of $488 million and other expenses of $226 million, primarily associated with acquisitions, restructuring actions and other expenses, as well as $85 million of additional transition tax related to the TCJA. See page 19 for additional details regarding specified items.

14

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

Year Ended December 31, 2019 and 2018

(in millions, except per share data)

(unaudited)

			12M19
			As Reported (GAAP)				Specified Items				As Adjusted				% to Sales
Intangible Amortization		$	1,936			$	(1,936	)			—
Gross Margin			16,737				2,140				18,877				59.2	%
R&D			2,440				(198	)			2,242				7.0	%
SG&A			9,765				(240	)			9,525				29.9	%
Debt extinguishment costs			63				(63	)			—
Other (income) expense, net			(191	)			(37	)			(228	)
Earnings from Continuing Operations before taxes			4,077				2,678				6,755
Tax expense on Earnings from Continuing Operations			390				555				945
Earnings from Continuing Operations			3,687				2,123				5,810
Diluted Earnings per Share from Continuing Operations		$	2.06			$	1.18			$	3.24

Specified items reflect intangible amortization expense of $1.936 billion and other expenses of $742 million, primarily associated with acquisitions, restructuring actions and other expenses. See page 20 for additional details regarding specified items.

			12M18
			As Reported (GAAP)				Specified Items				As Adjusted				% to Sales

Intangible Amortization		$	2,178			$	(2,178	)			—
Gross Margin			15,694				2,453				18,147				59.3	%
R&D			2,300				(87	)			2,213				7.2	%
SG&A			9,744				(365	)			9,379				30.7	%
Interest expense, net			721				(2	)			719
Net foreign exchange (gain) loss			28				(29	)			(1	)
Debt extinguishment costs			167				(167	)			—
Other (income) expense, net			(139	)			3				(136	)
Earnings from Continuing Operations before taxes			2,873				3,100				5,973
Tax expense on Earnings from Continuing Operations			539				303				842
Earnings from Continuing Operations			2,334				2,797				5,131
Diluted Earnings per Share from Continuing Operations		$	1.31			$	1.57			$	2.88

Specified items reflect intangible amortization expense of $2.178 billion and other expenses of $922 million, primarily associated with acquisitions, restructuring actions and other expenses. See page 21 for additional details regarding specified items.

15

A reconciliation of the fourth-quarter tax rates for continuing operations for 2019 and 2018 is shown below:

			4Q19
($ in millions)			Pre-Tax Income				Taxes on Earnings			Tax Rate
As reported (GAAP)		$	1,240			$	191			15.4	%
Specified items			714				58
Excluding specified items		$	1,954			$	249			12.8	%

			4Q18
($ in millions)			Pre-Tax Income				Taxes on Earnings			Tax Rate
As reported (GAAP)		$	947			$	292			30.8	%		1	)
Specified items			714				(75	)
Excluding specified items		$	1,661			$	217			13.1	%

1)

Reported tax rate on a GAAP basis for the fourth quarter of 2018 includes the impact of an additional $85 million of tax expense for the transition tax associated with the TCJA.

A reconciliation of the year-to-date tax rates for continuing operations for 2019 and 2018 is shown below:

			12M19
($ in millions)			Pre-Tax Income				Taxes on Earnings			Tax Rate
As reported (GAAP)		$	4,077			$	390			9.6	%		2	)
Specified items			2,678				555
Excluding specified items		$	6,755			$	945			14.0	%

			12M18
($ in millions)			Pre-Tax Income				Taxes on Earnings			Tax Rate
As reported (GAAP)		$	2,873			$	539			18.8	%		3	)
Specified items			3,100				303
Excluding specified items		$	5,973			$	842			14.1	%

2)

Reported tax rate on a GAAP basis for 2019 includes the impact of a $86 million reduction of the transition tax associated with the TCJA and approximately $100 million in excess tax benefits associated with share-based compensation.

3)

Reported tax rate on a GAAP basis for 2018 includes the impact of an additional $120 million of tax expense for the transition tax associated with the TCJA, as well as the impact of approximately $90 million in excess tax benefits associated with share-based compensation.

16

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Adjusted Historical Revenue

Year Ended December 31, 2019 and 2018

($ in millions) (unaudited)

			12M19				12M18												% Change vs. 12M18
			Abbott				Abbott				Discontinued				Adjusted								Non-GAAP
			Reported				Reported				Business^a)				Revenue				Reported				Reported				Organic^b)
Total Company			31,904				30,578				(38	)			30,540				4.3				4.5				7.7
U.S.			11,398				10,839				(38	)			10,801				5.2				5.5				5.5
Int'l			20,506				19,739				—				19,739				3.9				3.9				8.8
Total Nutrition			7,409				7,229				(38	)			7,191				2.5				3.0				5.3
U.S.			3,110				3,075				(38	)			3,037				1.1				2.4				2.4
Int'l			4,299				4,154				—				4,154				3.5				3.5				7.5
Adult			3,248				3,132				(38	)			3,094				3.7				5.0				7.9
U.S.			1,231				1,232				(38	)			1,194				(0.1	)			3.2				3.2
Int'l			2,017				1,900				—				1,900				6.2				6.2				10.9

a) Reflects sales related to a non-core product line within the U.S. Adult Nutrition business, which was discontinued during the third quarter 2018.

b) In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

17

Abbott Laboratories and Subsidiaries

Details of Specified Items

Fourth Quarter Ended December 31, 2019

(in millions, except per share data)

(unaudited)

		Acquisition or Divestiture- related (a)				Restructuring and Cost Reduction Initiatives (b)				Intangible Amortization				Other (c)				Total Specifieds
Gross Margin		$	34			$	28			$	483			$	—			$	545
R&D			(15	)			(22	)			—				(2	)			(39	)
SG&A			(39	)			(23	)			—				—				(62	)
Debt extinguishment costs			—				—				—				(63	)			(63	)
Other (income) expense, net			(5	)			—				—				—				(5	)
Earnings from Continuing Operations before taxes		$	93			$	73			$	483			$	65				714
Tax expense on Earnings from Continuing Operations (d)																			58
Earnings from Continuing Operations																		$	656
Diluted Earnings per Share from Continuing Operations																		$	0.36

The table above provides additional details regarding the specified items described on page 14.

a)

Acquisition-related expenses include costs for tax and other services related to business acquisitions, integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for retention, severance, and the integration of systems, processes and business activities.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, asset impairments, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

c)	Other primarily relates to costs associated with the early extinguishment of debt.

d)	Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

18

Abbott Laboratories and Subsidiaries

Details of Specified Items

Fourth Quarter Ended December 31, 2018

(in millions, except per share data)

(unaudited)

		Acquisition or Divestiture- related (a)				Restructuring and Cost Reduction Initiatives (b)				Intangible Amortization				Other (c)				Total Specifieds
Gross Margin		$	21			$	7			$	488			$	4			$	520
R&D			(7	)			5				—				—				(2	)
SG&A			(82	)			(9	)			—				—				(91	)
Net foreign exchange (gain) loss			—				(28	)			—				—				(28	)
Debt extinguishment costs			—				—				—				(86	)			(86	)
Other (income) expense, net			(1	)			—				—				14				13
Earnings from Continuing Operations before taxes		$	111			$	39			$	488			$	76				714
Tax expense on Earnings from Continuing Operations (d)																			(75	)
Earnings from Continuing Operations																		$	789
Diluted Earnings per Share from Continuing Operations																		$	0.44

The table above provides additional details regarding the specified items described on page 14.

a)

Acquisition-related expenses include costs for tax and other services related to business acquisitions, integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for retention, severance, and the integration of systems, processes and business activities, and fair value adjustments to contingent consideration related to a business acquisition.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, inventory write-downs, asset impairments, accelerated depreciation, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

c)	Other includes costs associated with the early extinguishment of debt, partially offset by a gain on investments.

d)	Reflects the net tax benefit associated with the specified items and additional tax expense for the transition tax associated with the TCJA.

19

Abbott Laboratories and Subsidiaries

Details of Specified Items

Year Ended December 31, 2019

(in millions, except per share data)

(unaudited)

		Acquisition or Divestiture- related (a)				Restructuring and Cost Reduction Initiatives (b)				Intangible Amortization				Other (c)				Total Specifieds
Gross Margin		$	103			$	101			$	1,936			$	—			$	2,140
R&D			(38	)			(44	)			—				(116	)			(198	)
SG&A			(153	)			(70	)			—				(17	)			(240	)
Debt extinguishment costs			—				—				—				(63	)			(63	)
Other (income) expense, net			(15	)			—				—				(22	)			(37	)
Earnings from Continuing Operations before taxes		$	309			$	215			$	1,936			$	218				2,678
Tax expense on Earnings from Continuing Operations (d)																			555
Earnings from Continuing Operations																		$	2,123
Diluted Earnings per Share from Continuing Operations																		$	1.18

The table above provides additional details regarding the specified items described on page 15.

a)

Acquisition-related expenses include costs for tax and other services related to business acquisitions, integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for retention, severance, and the integration of systems, processes and business activities, and fair value adjustments to contingent consideration related to a business acquisition.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, asset impairments, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

c)	Other relates to the acquisition of R&D assets, costs associated with the early extinguishment of debt, charges related to the impairment of certain assets, and expenses related to certain litigation settlements.

d)	Reflects the net tax benefit associated with the specified items, a reduction in the transition tax associated with the TCJA and excess tax benefits associated with share-based compensation.

20

Abbott Laboratories and Subsidiaries

Details of Specified Items

Year Ended December 31, 2018

(in millions, except per share data)

(unaudited)

		Acquisition or Divestiture- related (a)				Restructuring and Cost Reduction Initiatives (b)				Intangible Amortization				Other (c)				Total Specifieds
Gross Margin		$	123			$	106			$	2,178			$	46			$	2,453
R&D			(41	)			1				—				(47	)			(87	)
SG&A			(346	)			(19	)			—				—				(365	)
Interest expense, net			—				—				—				(2	)			(2	)
Net foreign exchange (gain) loss			—				(29	)			—				—				(29	)
Debt extinguishment costs			—				—				—				(167	)			(167	)
Other (income) expense, net			(2	)			—				—				5				3
Earnings from Continuing Operations before taxes		$	512			$	153			$	2,178			$	257				3,100
Tax expense on Earnings from Continuing Operations (d)																			303
Earnings from Continuing Operations																		$	2,797
Diluted Earnings per Share from Continuing Operations																		$	1.57

The table above provides additional details regarding the specified items described on page 15.

a)

Acquisition-related expenses include costs for legal, accounting, tax, and other services related to business acquisitions, integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for consulting, retention, severance, and the integration of systems, processes and business activities, fair value adjustments to contingent consideration related to a business acquisition, and inventory step-up amortization.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, inventory write-downs, asset impairments, accelerated depreciation, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

c)	Other includes the cost associated with the early extinguishment of debt, costs related to the acquisition of R&D assets and charges related to the impairment of certain assets, partially offset by a gain on investments.

d)	Reflects the net tax benefit associated with the specified items, additional tax expense for the transition tax associated with the TCJA and excess tax benefits associated with share-based compensation.

# # #

21

GRAPHIC 3 tm205456d1_ex99-1img001.jpg GRAPHIC begin 644 tm205456d1_ex99-1img001.jpg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end EX-101.SCH 4 abt-20200122.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 abt-20200122_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 abt-20200122_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] Entity Listings, Exchange [Axis] CHICAGO STOCK EXCHANGE, INC [Member] NEW YORK STOCK EXCHANGE, INC. [Member] Entity Listings [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 abt-20200122_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover	Jan. 22, 2020
Document Information [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 22, 2020
Entity File Number	1-2189
Entity Registrant Name	ABBOTT LABORATORIES
Entity Central Index Key	0000001800
Entity Tax Identification Number	36-0698440
Entity Incorporation, State or Country Code	IL
Entity Address, Address Line One	100 Abbott Park Road
Entity Address, City or Town	Abbott Park
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60064-6400
City Area Code	224
Local Phone Number	667-6100
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock [Member] \| CHICAGO STOCK EXCHANGE, INC [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Shares, Without Par Value
Trading Symbol	ABT
Security Exchange Name	CHX
Common Stock [Member] \| NEW YORK STOCK EXCHANGE, INC. [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Shares, Without Par Value
Trading Symbol	ABT
Security Exchange Name	NYSE

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 13 0001104659-20-005717-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-005717-xbrl.zip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end XML 14 tm205456d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000001800 2020-01-21 2020-01-22 0000001800 us-gaap:CommonStockMember exch:XCHI 2020-01-21 2020-01-22 0000001800 us-gaap:CommonStockMember exch:XNYS 2020-01-21 2020-01-22 iso4217:USD shares iso4217:USD shares 0000001800 false Common Shares, Without Par Value ABT 8-K 2020-01-22 ABBOTT LABORATORIES IL 1-2189 36-0698440 100 Abbott Park Road Abbott Park IL 60064-6400 224 667-6100 false false false false Common Shares, Without Par Value ABT NYSE CHX false XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 3 97 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://abbott.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm205456d1_8k.htm abt-20200122.xsd abt-20200122_def.xml abt-20200122_lab.xml abt-20200122_pre.xml tm205456d1_ex99-1.htm http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/exch/2019-01-31 true false XML 16 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm205456d1_8k.htm": { "axisCustom": 0, "axisStandard": 2, "contextCount": 3, "dts": { "definitionLink": { "local": [ "abt-20200122_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "tm205456d1_8k.htm" ] }, "labelLink": { "local": [ "abt-20200122_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "abt-20200122_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "abt-20200122.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 68, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 3, "nsprefix": "abt", "nsuri": "http://abbott.com/20200122", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm205456d1_8k.htm", "contextRef": "From2020-01-21to2020-01-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://abbott.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm205456d1_8k.htm", "contextRef": "From2020-01-21to2020-01-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHICAGO STOCK EXCHANGE, INC [Member]" } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" }